Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Comparison of butaperazine and perphenazine: A double-blind controlled study

  • 15 Accesses

  • 5 Citations

Summary

Fifty-three chronically ill institutionalized psychotic patients were placed on a double-blind study, using a newer phenothiazine, butaperazine, unmarketed in the United States, and a well-known and widely marketed compound, perphenazine. Matched patients received medication for a period of 8 weeks. Dosage of butaperazine was increased from 20 to 100 mg daily, and of perphenazine from 16 to 80 mg daily.

Butaperazine was found to be better than perphenazine in 8 pairs and equal to it in 5 pairs. Perphenazine was better than butaperazine in 12 pairs. Of the butaperazine patients, 1 showed moderate improvement, 9 were slightly improved, and 6 were slightly worse. In the perphenazine group, 7 were much improved, 10 slightly improved, and 3 slightly worse. The chief side effects in both groups were extrapyramidal phenomena, which responded to benztropine methanesulfonate.

These results indicate that in this chronic psychotic population, butaperazine does not seem to be a more effective compound than perphenazine, and has more side effects in the nature of extrapyramidal phenomena.

This is a preview of subscription content, log in to check access.

References

  1. Ayd jr., F. J.: The treatment of anxiety, agitation and excitement in the aged. J. Amer. Geriat. Soc. 5, 92–96 (1957).

  2. Cahn, C. H., and H. E. Lehmann: Perphenazine: observations on the clinical effects of a new tranquilizing agent in psychotic conditions. Canad. psychiat. Ass. J. 2, 101–112 (1957).

  3. Denber, H., E. Ross and P. Rajotte: Study of butyrylperazine (Bayer 1362). Amer. J. Psychiat. 117, 1119–1120 (1961).

  4. Freyhan, F. A.: Therapeutic implications of differential effects of new phenothiazine compounds. Amer. J. Psychiat. 115, 577–585 (1959).

  5. Settel, E.: The use of perphenazine (Trilafon) to control anxiety and agitation in aged patients. J. Amer. Geriat. Soc. 5, 1003–1008 (1957).

Download references

Author information

Additional information

This study was supported in part by Research Grant MH-05106-02, National Institute of Mental Health, United States Public Health Service.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Sharpley, P., Heistad, G. & Schiele, B.C. Comparison of butaperazine and perphenazine: A double-blind controlled study. Psychopharmacologia 5, 209–216 (1964). https://doi.org/10.1007/BF00413243

Download citation

Keywords

  • United States
  • Phenothiazine
  • Methanesulfonate
  • Moderate Improvement
  • Perphenazine